Verseau Therapeutics
Bedford
About Verseau Therapeutics
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. The company's modulators identify novel targets and develop therapies that shift macrophages between immune activators and silencers in disease, enabling physicians to benefit patients from immunotherapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $54.3M
- Last round: Series Unknown (Oct 2019)
- Website: verseautx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/verseau-therapeutics-38628 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.